1146 related articles for article (PubMed ID: 21896352)
1. The future of pneumococcal disease prevention.
Rodgers GL; Klugman KP
Vaccine; 2011 Sep; 29 Suppl 3():C43-8. PubMed ID: 21896352
[TBL] [Abstract][Full Text] [Related]
2. Pneumococcal conjugated vaccine: PHiD-CV.
Dinleyici EC; Yargic ZA
Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1063-74. PubMed ID: 19883326
[TBL] [Abstract][Full Text] [Related]
3. The pharmacoeconomics of pneumococcal conjugate vaccines in Latin America.
Giglio N; Micone P; Gentile A
Vaccine; 2011 Sep; 29 Suppl 3():C35-42. PubMed ID: 21896351
[TBL] [Abstract][Full Text] [Related]
4. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines.
Isaacman DJ; McIntosh ED; Reinert RR
Int J Infect Dis; 2010 Mar; 14(3):e197-209. PubMed ID: 19700359
[TBL] [Abstract][Full Text] [Related]
5. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):253-7. PubMed ID: 20224541
[TBL] [Abstract][Full Text] [Related]
6. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model.
Skinner JM; Indrawati L; Cannon J; Blue J; Winters M; Macnair J; Pujar N; Manger W; Zhang Y; Antonello J; Shiver J; Caulfield M; Heinrichs JH
Vaccine; 2011 Nov; 29(48):8870-6. PubMed ID: 21964055
[TBL] [Abstract][Full Text] [Related]
7. Herd immunity and pneumococcal conjugate vaccine: a quantitative model.
Haber M; Barskey A; Baughman W; Barker L; Whitney CG; Shaw KM; Orenstein W; Stephens DS
Vaccine; 2007 Jul; 25(29):5390-8. PubMed ID: 17583392
[TBL] [Abstract][Full Text] [Related]
8. Prevenar experience.
Arguedas A; Soley C; Abdelnour A
Vaccine; 2011 Sep; 29 Suppl 3():C26-34. PubMed ID: 21896350
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.
Bryant KA; Block SL; Baker SA; Gruber WC; Scott DA;
Pediatrics; 2010 May; 125(5):866-75. PubMed ID: 20435707
[TBL] [Abstract][Full Text] [Related]
10. Pneumococcal conjugate vaccine for young children.
Selman S; Hayes D; Perin LA; Hayes WS
Manag Care; 2000 Sep; 9(9):49-52, 54, 56-7 passim. PubMed ID: 11116663
[TBL] [Abstract][Full Text] [Related]
11. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
Nuorti JP; Whitney CG;
MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
[TBL] [Abstract][Full Text] [Related]
12. Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine.
Dinleyici EC; Yargic ZA
Expert Rev Vaccines; 2009 Aug; 8(8):977-86. PubMed ID: 19627181
[TBL] [Abstract][Full Text] [Related]
13. Progress in introduction of pneumococcal conjugate vaccine--worldwide, 2000-2008.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2008 Oct; 57(42):1148-51. PubMed ID: 18946462
[TBL] [Abstract][Full Text] [Related]
14. Pneumococcal serotype evolution in Western Europe.
Tin Tin Htar M; Christopoulou D; Schmitt HJ
BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008
[TBL] [Abstract][Full Text] [Related]
15. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines.
Shouval DS; Greenberg D; Givon-Lavi N; Porat N; Dagan R
Pediatr Infect Dis J; 2009 Apr; 28(4):277-82. PubMed ID: 19258924
[TBL] [Abstract][Full Text] [Related]
16. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine.
Muñoz-Almagro C; Jordan I; Gene A; Latorre C; Garcia-Garcia JJ; Pallares R
Clin Infect Dis; 2008 Jan; 46(2):174-82. PubMed ID: 18171247
[TBL] [Abstract][Full Text] [Related]
17. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections.
Zangeneh TT; Baracco G; Al-Tawfiq JA
Expert Rev Vaccines; 2011 Mar; 10(3):345-53. PubMed ID: 21434802
[TBL] [Abstract][Full Text] [Related]
18. Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children.
Tocheva AS; Jefferies JM; Rubery H; Bennett J; Afimeke G; Garland J; Christodoulides M; Faust SN; Clarke SC
Vaccine; 2011 Jun; 29(26):4400-4. PubMed ID: 21504773
[TBL] [Abstract][Full Text] [Related]
19. Pneumococcal conjugate vaccines. A review.
Galiza EP; Heath PT
Minerva Med; 2007 Apr; 98(2):131-43. PubMed ID: 17519855
[TBL] [Abstract][Full Text] [Related]
20. Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.
Weil-Olivier C; van der Linden M; de Schutter I; Dagan R; Mantovani L
BMC Infect Dis; 2012 Sep; 12():207. PubMed ID: 22954038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
